CLAIMS

1. A compound of formula (I) in crystalline form of polymorph I



,

wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 22.7.

2. The compound of claim 1, wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 5.9, 6.9, 16.2, 16.5, 24.1, 22.7, 24.7.

3. The compound of claim 1, wherein the IR spectrum of the compound exhibits band maxima at 1707, 1633, 1475 cm^{-1}.

4. The compound of claim 3, wherein the IR spectrum of the compound exhibits band maxima at 1707, 1633, 1566, 1475, 1255, 1223 cm^{-1}.

5. A process for preparing the compound of claim 1, comprising:

stirring a solution of compounds of formula (I), wherein the compounds of formula (I) are present in one or more polymorphs or as a solvate in an inert solvent, at a temperature of 20° C.-120° C., and

isolating the compound of formula (I) in the form of crystalline polymorph I from the solution.

6. A solid pharmaceutical composition comprising a compound of claim 1 and no greater proportion of any other form of the compound of the formula (I).

7. A solid pharmaceutical composition comprising a compound of claim 1 in more than 90 percent by weight based on the total amount any other form of the compound of the formula (I) present.

8. A compound of claim 1 for use in the treatment of a disorder.

9. Use of a compound of claim 1 in the manufacture of a medicament for the treatment of cardiovascular disorders.